



Age 12+

ICS Inhaler Estimated Dose Categories in Adults and Adolescents 12 Years and Older

Age 12+

Brand	Alvesco	Arnuity Ellipta	Asmanex HFA	Asmanex Twisthaler	Flovent Diskus	Flovent HFA	Pulmicort Flexhaler	QVAR RediHaler
Generic Delivery	Ciclesonide METERED DOSE	Fluticasone furoate DRY POWDER	Mometasone METERED DOSE	Mometasone DRY POWDER	Fluticasone prop. DRY POWDER	Fluticasone prop. METERED DOSE	Budesonide DRY POWDER	Beclomethasone METERED DOSE
Indication	A Asthma: 12+ yrs	A Asthma: 5+ yrs	A Asthma: 5+ yrs	A Asthma: 4+ yrs	A Asthma: 4+ yrs	A Asthma: 4+ yrs	A Asthma: 6+ yrs	A Asthma: 4+ yrs
Available Product Strengths	80 mcg/inh 160 mcg/inh	50 mcg/inh 100 mcg/inh 200 mcg/inh	50 mcg/inh 100 mcg/inh 200 mcg/inh	110 mcg/inh 220 mcg/inh	50 mcg/inh 100 mcg/inh 250 mcg/inh	44 mcg/inh 110 mcg/inh 220 mcg/inh	90 mcg/inh 180 mcg/inh	40 mcg/inh 80 mcg/inh
Low Dose†	1 puff BID	1 inh. QD 1 inh. QD	1 puff* BID	1 inh. QD	1 inh. BID	2 puffs BID 1 puff BID	1-2 inh. BID 1 inh. BID	1-2 puffs BID 1 puff BID
Medium Dose†	1 puff BID		2 puffs BID 1 puff* BID	2 inh. QD or 1 inh. BID	2 inh. BID 1 inh. BID	2 puffs BID 1 puff BID	2 inh. BID	2 puffs BID
High Dose†	2 puffs BID	1 inh. QD	2 puffs BID	2 inh. BID	2-4 inh. BID	2-4 puffs BID	3-4 inh. BID	3-4 puffs BID



Age 12+

ICS/LABA and ICS/LAMA/LABA Inhaler Estimated Dose Categories in Adults and Adolescents 12 Years and Older

Age 12+

Brand	Breo Ellipta	Dulera	Advair Diskus Generic: Wixela Inhub	Advair HFA	AirDuo RespiClick	Symbicort Generic: Breyna	Breztri Aerosphere	Trelegy Ellipta
Generic Delivery	Fluticasone fur./ Vilanterol DRY POWDER	Mometasone/ Formoterol METERED DOSE	Fluticasone prop./ Salmeterol DRY POWDER	Fluticasone prop./ Salmeterol METERED DOSE	Fluticasone prop./ Salmeterol DRY POWDER	Budesonide/ Formoterol METERED DOSE	Budesonide/ Glycopyrrolate/ Formoterol METERED DOSE	Fluticasone fur./ Umeclidinium/ Vilanterol DRY POWDER
Indication	A Asthma: 5+ yrs C COPD	A Asthma: 5+ years	A Asthma: 4+ years C COPD	A Asthma: 12+ years	A Asthma: 12+ years	A Asthma: 6+ years C COPD	C COPD	A Asthma: 18+ yrs C COPD
Available Product Strengths	50/25 mcg/inh 100/25 mcg/inh 200/25 mcg/inh	50/5 mcg/inh 100/5 mcg/inh 200/5 mcg/inh	100/50 mcg/inh 250/50 mcg/inh 500/50 mcg/inh	45/21 mcg/inh 115/21 mcg/inh 230/21 mcg/inh	55/14 mcg/inh 113/14 mcg/inh 232/14 mcg/inh	80/4.5 mcg/inh 160/4.5 mcg/inh	160/9/4.8 mcg/inh	100/62.5/25 mcg/inh 200/62.5/25 mcg/inh
Low Dose†			1 inh. BID	2 puffs BID 1 puff* BID	1 inh. BID	2 puffs BID 1 puff* BID	1 puff* BID	
Medium Dose†	1 inh. QD	1*-2 puffs BID 1 puff* BID	1 inh. BID	2 puffs BID 1 puff* BID	1 inh. BID	2 puffs BID	2 puffs BID	1 inh. QD
High Dose†	1 inh. QD	2 puffs BID	1 inh. BID	2 puffs BID	1 inh. BID			1 inh. QD

Notes

The most important determinant of appropriate dosing is the clinician's judgment of the patient's response to therapy. The definitions of "low", "medium", and "high" dose ICS may vary by source. Where applicable, this resource reflects updated guidance from GINA 2023 which contains more conservative dose recommendations for these categories than previous GINA reports and NHLBI EPR-3 based upon recognition that generally the most benefit is obtained with the low dose; however, ICS response varies by the individual. References: NHLBI EPR 2007 and 2020 Focused Updates to the Asthma Management Guidelines, 2023 GINA Report: Global Strategy for Asthma Management and Prevention, manufacturer product information.

*Off-label dosing regimen

† View manufacturer product information regarding disease-specific dosing and titration

Disclaimer: Data on comparative potency of ICS-containing medications is limited. This document does not present equivalent dosing information, but presents estimated dose categorizations based upon recognized clinical guidance for the treatment of asthma and manufacturer product labeling.

© 2024 Cosmas Health, Inc. and/or its affiliates. | More clinical pearls at pyrils.com.

Published January 2024



ICS-Containing Inhaler Estimated Dose Categorizations Adults and Adolescents 12 Years and Older



Children Age 5-11

ICS Inhaler Estimated Dose Categories in Children Age 5-11 Years

Children Age 5-11

Brand	Alvesco	Arnuity Ellipta	Asmanex HFA	Asmanex Twisthaler	Flovent Diskus	Flovent HFA	Pulmicort Flexhaler	Pulmicort Respules	QVAR RediHaler
Generic Delivery	Ciclesonide METERED DOSE	Fluticasone furoate DRY POWDER	Mometasone METERED DOSE	Mometasone DRY POWDER	Fluticasone prop. DRY POWDER	Fluticasone prop. METERED DOSE	Budesonide DRY POWDER	Budesonide NEBULIZER SUSPENSION	Beclomethasone METERED DOSE
Age Indicated	A Asthma: 12+ yrs	A Asthma: 5+ yrs	A Asthma: 5+ yrs	A Asthma: 4+ yrs	A Asthma: 4+ yrs	A Asthma: 4+ yrs	A Asthma: 6+ yrs	A Asthma: 12 months to 8 yrs	A Asthma: 4+ yrs
Available Product Strengths	80 mcg/inh 160 mcg/inh	50 mcg/inh 100 mcg/inh 200 mcg/inh	50 mcg/inh 100 mcg/inh 200 mcg/inh	110 mcg/inh 220 mcg/inh	50 mcg/inh 100 mcg/inh 250 mcg/inh	44 mcg/inh 110 mcg/inh 220 mcg/inh	90 mcg/inh 180 mcg/inh	0.25 mg /2 mL 0.5 mg /2 mL 1 mg /2 mL	40 mcg/inh 80 mcg/inh
Low Dose†	1 puff* QD	1 inh. QD	1 puff* BID 1 puff* QD	1 inh. QD	1 inh. BID	1 puff BID	1 inh. BID	1 vial QD or BID 1 vial QD	1 puff BID
Medium Dose†	1 puff BID				1 inh. BID	2 puffs BID 1-2 puffs BID	2 inh. BID 1 inh. BID	1 vial BID 1 vial QD	2 puffs BID 1 puff BID
High Dose†	1 puffs BID		2 puffs BID 1 puff BID 1 puff* QD		1 inh.* QD	3-4 puffs BID 1 puff BID	2 inh. BID	1 vial BID	3-4 puffs BID 2 puffs BID
Notes	Approved in age 12+ in the US [^]	FDA recommended daily dose is 50 mcg in age 5 to 11 years	FDA max daily dose is 200 mcg in age 5 to 11 years	FDA max daily dose is 110 mcg in age 4-11 yrs	FDA max recommended dose is 100 mcg BID in age 4 to 11 years	FDA recommended dose is 88 mcg BID in age 4 to 11 years	FDA max dose is 360 mcg BID in age 6-17 yrs	FDA max daily dose is 1 mg in age 12 months to 8 years	FDA max dose is 80 mcg BID in age 4-11 yrs



Children Age 5-11

ICS/LABA Estimated Dose Categories

Brand	Advair Diskus	Breo Ellipta	Dulera	Symbicort
Generic Delivery	Generic: Wixela Inhub Fluticasone prop./ Salmeterol DRY POWDER	Fluticasone fur./ Vilanterol DRY POWDER	Mometasone/ Formoterol METERED DOSE	Generic: Breyna Budesonide/ Formoterol METERED DOSE
Age Indicated	A Asthma: 4+ years	A Asthma: 5+ yrs	A Asthma: 5+ years	A Asthma: 6+ years
Available Product Strengths	100/50 mcg/inh 250/50 mcg/inh 500/50 mcg/inh	50/25 mcg/inh 100/25 mcg/inh 200/25 mcg/inh	50/5 mcg/inh 100/5 mcg/inh 200/5 mcg/inh	80/4,5 mcg/inh 160/4,5 mcg/inh
Low Dose†	1 inh QD*	1 inh. QD	1 puff* BID 1 puff* QD*	1 puff* BID 1 puff* QD*
Medium Dose†	1 inh BID			2 puffs BID 1 puff* BID
High Dose†	1 inh QD*		2 puffs BID 1 puff* BID 1 puff* QD*	
Notes	FDA max rec'd dose: 100/50 mcg BID in age 4 to 11 years	FDA max rec'd dose: 50/25 mcg QD in age 5 to 11 years	FDA max daily dose: 200/20 mcg in age 5 to 11 years	FDA rec'd dose: 160/9 mcg BID in age 6-11 yrs

ICS-Containing Medication Estimated Dose Categorizations

Children Age 5-11 Years

Disclaimer: Data on comparative potency of ICS-containing medications is limited. This document does not present equipotent dosing information, but presents estimated dose categorizations based upon recognized clinical guidance for the treatment of asthma and manufacturer product labeling.

Published January 2024

© 2024 Cosmas Health, Inc. and/or its affiliates. | More clinical pearls at pyrls.com.



* Off-label per FDA-approved dosing regimen

† View region-specific manufacturer product information regarding disease-specific dosing and titration

[^] Ciclesonide is FDA-approved in the US for those age 12+ years. It is approved for age 6+ years in Canada, and also varies elsewhere.

The most important determinant of appropriate dosing is the clinician's judgment of the patient's response to therapy.

The definitions of "low", "medium", and "high" dose ICS may vary by source. Where applicable, this resource reflects updated guidance from GINA 2023 which contains more conservative dose recommendations for these categories than previous GINA reports and NHLBI EPR-3 based upon recognition that generally the most benefit is obtained with the low dose; however, ICS response varies by the individual.

References: NHLBI EPR 2007 and 2020 Focused Updates to the Asthma Management Guidelines, 2023 GINA Report: Global Strategy for Asthma Management and Prevention, manufacturer product information for the individual medications

Notes: